On April 30, 2026 Prescient Therapeutics Ltd (ASX:PTX) reported continued progress across its oncology development pipeline during the March 2026 quarter, led by expanding enrolment and site activation in its PTX-100 Phase 2a clinical program.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The company’s global Phase 2a study of PTX-100 in Cutaneous T-cell Lymphoma (CTCL) continued to build momentum, with two new Italian sites activated during the quarter, taking the total number of active sites to 11 at March 31.

A further Italian site was activated after quarter-end, lifting the active global site count to 12, with European expansion expected to increase the total to up to 16 sites.

Enrolment advancing
Patient enrolment also advanced, with six patients enrolled during the quarter for a total of 12 at quarter-end. A further 6 patients were enrolled across the US, Australia and Italy by April 24, increasing total enrolment to 18 patients. The Phase 2a protocol allows enrolment of up to 40 patients.

Prescient also reported progress in understanding PTX-100’s mode of action through its collaboration with CSIRO. Using artificial intelligence and advanced computational modelling, scientists constructed a 3D model of PTX-100’s interaction with its target protein.

The modelling showed PTX-100 binds tightly to its target and blocks the active site with high selectivity, a profile the company said may support efficacy across target protein conformations and reduce the likelihood of resistance emerging in cancer cells.

Prescient’s earlier Phase 1b study has now fully closed following completion of the clinical study report. One patient remains on PTX-100 through compassionate access after 2.5 years, reflecting durable clinical benefit in that individual.

Data generation
The company continues to assess opportunities to generate additional clinical data for PTX-100 in Peripheral T-cell Lymphoma, with further studies to be considered after selection of the recommended Phase 2 dose for CTCL.

Across its cell therapy platforms, business development discussions continued during the quarter for both OmniCAR and CellPryme, with further updates to be provided as material developments occur.

Prescient ended the quarter with cash and term deposits of $11.93 million, following receipt of a $4.3 million R&D tax refund in January 2026. Net operating cash outflows totalled $2.21 million, including $1.17 million invested in research and development and clinical activities.

CEO James McDonnell will host an online investor briefing on Tuesday, May 5, 2026, at 12pm AEST. Registration is available here: View Source

(Press release, Prescient Therapeutics, APR 30, 2026, View Source;utm_medium=rss&utm_campaign=prescient-therapeutics-advances-ptx-100-trial-and-cell-therapy-platforms [SID1234668718])